{"id":"olanzapine-therapy","safety":{"commonSideEffects":[{"rate":"~10-15%","effect":"Weight gain"},{"rate":"~20-26%","effect":"Sedation/somnolence"},{"rate":"~11-16%","effect":"Dizziness"},{"rate":"~5-10%","effect":"Hyperglycemia/diabetes"},{"rate":"~5-10%","effect":"Hyperlipidemia"},{"rate":"~5-10%","effect":"Akathisia"},{"rate":"~5-10%","effect":"Orthostatic hypotension"}]},"_chembl":{"chemblId":"CHEMBL3989694","moleculeType":"Small molecule","molecularWeight":"718.83"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Olanzapine antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis such as hallucinations and delusions. It also blocks serotonin 5-HT2A receptors, which contributes to its efficacy in treating negative symptoms and mood disturbances. The combined dopaminergic and serotonergic antagonism makes it effective across multiple psychiatric conditions.","oneSentence":"Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:58:05.031Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute mania and maintenance)"},{"name":"Acute agitation associated with schizophrenia or bipolar disorder"},{"name":"Treatment-resistant depression (in combination with fluoxetine)"}]},"trialDetails":[{"nctId":"NCT07482891","phase":"PHASE4","title":"An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai 6th People's Hospital","startDate":"2026-03-10","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":200},{"nctId":"NCT05693935","phase":"PHASE3","title":"A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D LLC","startDate":"2023-01-24","conditions":"Schizophrenia","enrollment":675},{"nctId":"NCT04939090","phase":"PHASE3","title":"Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2022-01-03","conditions":"Advanced Malignant Solid Neoplasm, Anorexia, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":360},{"nctId":"NCT07208305","phase":"PHASE3","title":"Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting","status":"RECRUITING","sponsor":"Affiliated Hospital of Qinghai University","startDate":"2026-02-03","conditions":"Nausea, Vomiting","enrollment":222},{"nctId":"NCT05741502","phase":"PHASE4","title":"An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine","status":"TERMINATED","sponsor":"Ohio State University","startDate":"2023-08-16","conditions":"Treatment-resistant Schizophrenia","enrollment":5},{"nctId":"NCT06995508","phase":"PHASE2","title":"Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2025-12-24","conditions":"Cancer-Associated Anorexia, Head and Neck Squamous Cell Carcinoma, Neck Squamous Cell Carcinoma of Unknown Primary","enrollment":66},{"nctId":"NCT00183625","phase":"PHASE4","title":"Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2000-06","conditions":"Schizophrenia","enrollment":107},{"nctId":"NCT07047651","phase":"PHASE4","title":"Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.","status":"RECRUITING","sponsor":"Dr. Stavroula Rakitzi","startDate":"2025-06-04","conditions":"Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder","enrollment":40},{"nctId":"NCT02926859","phase":"PHASE2","title":"Enhancing Recovery in Early Schizophrenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2017-04-08","conditions":"Schizophrenia","enrollment":180},{"nctId":"NCT05814640","phase":"PHASE1, PHASE2","title":"Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-02-20","conditions":"Depression, Sequestra","enrollment":520},{"nctId":"NCT04216329","phase":"PHASE1","title":"Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-07","conditions":"Gliosarcoma, Newly Diagnosed, Glioblastoma","enrollment":11},{"nctId":"NCT05705492","phase":"PHASE2","title":"Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2024-07-17","conditions":"Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma, Advanced Esophageal Carcinoma","enrollment":66},{"nctId":"NCT06952920","phase":"PHASE3","title":"Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2025-08-21","conditions":"Standard Quadruple Antiemetic Therapy, Electroacupuncture, Chemotherapy-induced Gastrointestinal Symptom Cluster","enrollment":388},{"nctId":"NCT07263191","phase":"","title":"A Study of Olanzapine in Participants With Bipolar Disorder.","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2025-10-30","conditions":"Bipolar Disorder","enrollment":3000},{"nctId":"NCT07246187","phase":"PHASE3","title":"Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department","status":"RECRUITING","sponsor":"Mercy Bon Secours Saint Vincent Medical Center","startDate":"2025-11-06","conditions":"Cannabinoid Hyperemesis Syndrome","enrollment":114},{"nctId":"NCT05590923","phase":"PHASE4","title":"Steroid-sparing Therapy (Olanzapine) Versus Dexamethasone-based Therapy for Chemotherapy-induced Nausea and Vomiting","status":"TERMINATED","sponsor":"The Guthrie Clinic","startDate":"2022-12-07","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":24},{"nctId":"NCT06049953","phase":"","title":"Maternal And Infant Antipsychotic Study","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-09-29","conditions":"Antipsychotics, Pregnancy","enrollment":200},{"nctId":"NCT03367572","phase":"PHASE3","title":"Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer","status":"COMPLETED","sponsor":"University of Rochester NCORP Research Base","startDate":"2018-04-19","conditions":"Breast Carcinoma","enrollment":1363},{"nctId":"NCT07190482","phase":"PHASE1","title":"Treatment of Tinnitus With Olanzapine","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2023-10-01","conditions":"Tinnitus, Tinnitus, Subjective","enrollment":50},{"nctId":"NCT06175273","phase":"PHASE2, PHASE3","title":"Pediatric Oncology Nutrition Intervention Trial","status":"COMPLETED","sponsor":"Corey Hawes","startDate":"2024-01-31","conditions":"Pediatric Cancer, Nutrition Related Cancer, Nutrition Aspect of Cancer","enrollment":19},{"nctId":"NCT07152184","phase":"PHASE2","title":"Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-01-01","conditions":"Patient With Schizophrenia Spectrum Disorder, NLM Classification WM 203, Psychology:Schizophrenic Psychology, Schizophrenia Spectrum and Other Psychotic Disorders","enrollment":288},{"nctId":"NCT02634463","phase":"PHASE1","title":"Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-11-09","conditions":"Immunoassay, Antipsychotic","enrollment":81},{"nctId":"NCT07035821","phase":"PHASE3","title":"Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Children's Medical Center","startDate":"2025-07-01","conditions":"Breakthrough Chemotherapy-Induced Vomiting (CIV) in Pediatric Patients, Pediatric Cancer","enrollment":100},{"nctId":"NCT06949657","phase":"NA","title":"Occurrence and Influencing Factors of Cognitive Impairment in Elderly Patients With Schizophrenia and","status":"TERMINATED","sponsor":"Third People's Hospital, Huzhou City, Zhejiang Province, China","startDate":"2023-10-13","conditions":"Schizophrenia Disorders, Cognitive Impairment, Acceptance and Commitment Therapy","enrollment":78},{"nctId":"NCT06754163","phase":"PHASE4","title":"Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients","status":"RECRUITING","sponsor":"St Andrew's Healthcare","startDate":"2025-01-01","conditions":"Obesity and Obesity-related Medical Conditions, Psychiatric Disorders","enrollment":20},{"nctId":"NCT04478838","phase":"PHASE4","title":"\"Extended\" (Alternate Day) Antipsychotic Dosing","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2022-06-06","conditions":"Schizophrenia and Related Disorders, Drug Administration Schedule, Drug Therapy","enrollment":120},{"nctId":"NCT02431702","phase":"PHASE3","title":"A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-07-08","conditions":"Schizophrenia, Psychotic Disorders","enrollment":337},{"nctId":"NCT03666715","phase":"","title":"A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal","status":"COMPLETED","sponsor":"Janssen-Cilag Farmaceutica Ltda.","startDate":"2018-08-07","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT03629951","phase":"","title":"A Study for Schizophrenia Relapse Prediction","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-11-29","conditions":"Schizophrenia","enrollment":333},{"nctId":"NCT03510325","phase":"PHASE3","title":"Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2019-02-12","conditions":"Schizophrenia","enrollment":762},{"nctId":"NCT03578081","phase":"PHASE3","title":"Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2018-11-20","conditions":"Malignant Neoplasm","enrollment":690},{"nctId":"NCT06200168","phase":"PHASE3","title":"Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2024-01-16","conditions":"Electroacupuncture, Olanzapine-contained Four-drug Antiemetic, Nausea and Vomiting","enrollment":370},{"nctId":"NCT06107803","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia","status":"COMPLETED","sponsor":"Minerva Neurosciences","startDate":"2023-10-13","conditions":"Negative Symptoms in Schizophrenia","enrollment":17},{"nctId":"NCT02237417","phase":"PHASE4","title":"Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-09-01","conditions":"Schizophrenia","enrollment":47},{"nctId":"NCT02116530","phase":"PHASE3","title":"Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2014-08-20","conditions":"Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":401},{"nctId":"NCT05895838","phase":"PHASE3","title":"The Danish Out-of-Hospital Cardiac Arrest Study","status":"RECRUITING","sponsor":"Christian Hassager","startDate":"2023-06-16","conditions":"Out-Of-Hospital Cardiac Arrest, Post-Cardiac Arrest Syndrome","enrollment":1000},{"nctId":"NCT00512070","phase":"NA","title":"Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine","status":"COMPLETED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2007-07","conditions":"Schizophrenia, Schizoaffective Disorder, Bipolar Disorder","enrollment":40},{"nctId":"NCT02088060","phase":"PHASE2","title":"A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients","status":"TERMINATED","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2015-12-08","conditions":"Schizophrenia","enrollment":150},{"nctId":"NCT03030417","phase":"PHASE1","title":"Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-02-27","conditions":"Solid Tumors, Lymphoma","enrollment":36},{"nctId":"NCT02958800","phase":"NA","title":"Deprescribing Antipsychotics in Long-Term Care","status":"COMPLETED","sponsor":"McMaster University","startDate":"2016-12","conditions":"Dementia, Behavior","enrollment":6},{"nctId":"NCT03557931","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-07-13","conditions":"Schizophrenia","enrollment":233},{"nctId":"NCT06613334","phase":"NA","title":"Voice-Based Biomarkers: a Novel Approach to Monitoring and Predicting Schizophrenia Relapses","status":"RECRUITING","sponsor":"Centre Hospitalier St Anne","startDate":"2024-10-04","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT01029769","phase":"NA","title":"Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2009-12","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":350},{"nctId":"NCT03201757","phase":"PHASE3","title":"Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2017-06-15","conditions":"Schizophrenia, Schizophreniform Disorder, Bipolar I Disorder","enrollment":523},{"nctId":"NCT04892199","phase":"PHASE4","title":"Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anders Fink-Jensen, MD, DMSci","startDate":"2021-09-01","conditions":"Metabolic Disturbance, Schizophrenia, Type 2 Diabetes","enrollment":104},{"nctId":"NCT04876521","phase":"PHASE4","title":"Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in Post-Schizophrenic Depression","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2019-10-14","conditions":"Post-Schizophrenic Depression","enrollment":60},{"nctId":"NCT04218981","phase":"NA","title":"Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental Disorders","status":"COMPLETED","sponsor":"Central South University","startDate":"2020-01-15","conditions":"Common Mental Disorder","enrollment":200},{"nctId":"NCT00143182","phase":"PHASE3","title":"9 Week Extension Study of Asenapine and Olanzapine in Treatment of Mania (P07007)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-01-07","conditions":"Bipolar Disorder","enrollment":504},{"nctId":"NCT00159796","phase":"PHASE3","title":"3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-12-14","conditions":"Bipolar Disorder","enrollment":489},{"nctId":"NCT00159744","phase":"PHASE3","title":"3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-11-30","conditions":"Bipolar Disorder","enrollment":488},{"nctId":"NCT06554613","phase":"PHASE2","title":"Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2024-12-01","conditions":"Non-Small Cell Lung Cancer","enrollment":156},{"nctId":"NCT00212784","phase":"PHASE3","title":"Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-09-04","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":1225},{"nctId":"NCT06482554","phase":"PHASE3","title":"Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.","status":"RECRUITING","sponsor":"Louisiana State University Health Sciences Center Shreveport","startDate":"2024-06","conditions":"Apathy, Schizophrenia, Schizophrenia; Psychosis","enrollment":80},{"nctId":"NCT05402111","phase":"PHASE1","title":"A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-06-13","conditions":"Schizophrenia","enrollment":31},{"nctId":"NCT05542264","phase":"PHASE1","title":"A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-11-15","conditions":"Schizophrenia","enrollment":19},{"nctId":"NCT06133114","phase":"PHASE4","title":"Psychopharmacological Treatment of Emotional Distress","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2024-03-13","conditions":"Suicide Crisis Syndrome, Psychological Distress","enrollment":80},{"nctId":"NCT05403580","phase":"PHASE3","title":"Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2022-06-03","conditions":"Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":""},{"nctId":"NCT04478526","phase":"NA","title":"Efficacy of Online CBT for GAD Compared to Pharmaceutical Interventions","status":"COMPLETED","sponsor":"Dr. Nazanin Alavi","startDate":"2020-04-29","conditions":"Generalized Anxiety Disorder","enrollment":115},{"nctId":"NCT06357104","phase":"PHASE4","title":"Detoxification From the Lipid Tract","status":"COMPLETED","sponsor":"Pachankis, Yang I., M.D.","startDate":"2024-02-26","conditions":"COVID-19 Vaccine Adverse Reaction","enrollment":1},{"nctId":"NCT06338683","phase":"PHASE3","title":"Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer","status":"RECRUITING","sponsor":"Qinghai Red Cross Hospital","startDate":"2024-03-20","conditions":"Advanced Cancer, Olanzapine, Progression Free Survival","enrollment":230},{"nctId":"NCT06326840","phase":"NA","title":"Clinical Efficacy and Adverse Reactions of Antipsychotic Treatment","status":"COMPLETED","sponsor":"Taipei Medical University Hospital","startDate":"2010-05-31","conditions":"Metabolic Disturbance, Hyperprolactinemia, Schizophrenia","enrollment":42},{"nctId":"NCT06314906","phase":"PHASE3","title":"Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer","status":"RECRUITING","sponsor":"Feixue Song","startDate":"2024-03-07","conditions":"Electroacupuncture, Olanzapine-contained Four-drug Antiemetic, Nausea and Vomiting","enrollment":370},{"nctId":"NCT04529226","phase":"PHASE2","title":"Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2020-11-26","conditions":"Psychosis, Intellectual Disability","enrollment":75},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT00876772","phase":"PHASE2, PHASE3","title":"Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2011-03","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":40},{"nctId":"NCT06200584","phase":"NA","title":"Synergistic Effect of Vitamin E & D in Reducing Risk of Effects Associated With Atypical Anti-psychotics","status":"COMPLETED","sponsor":"Dr Rabia Arshad","startDate":"2021-01-01","conditions":"Antipsychotics and Neuroleptics Toxicity","enrollment":140},{"nctId":"NCT06159322","phase":"","title":"Characterizing Response to Antipsychotics in Schizophrenia","status":"UNKNOWN","sponsor":"The Royal Ottawa Mental Health Centre","startDate":"2023-01-01","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":40},{"nctId":"NCT06128408","phase":"","title":"The Characteristics of Treatment Resistant Schizophrenia From the Illness Onset","status":"UNKNOWN","sponsor":"Peking University","startDate":"2023-12-01","conditions":"Treatment-resistant Schizophrenia","enrollment":300},{"nctId":"NCT05163717","phase":"PHASE2","title":"INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASD","status":"TERMINATED","sponsor":"Impel Pharmaceuticals","startDate":"2022-06-23","conditions":"Agitation in Adolescents and Young Adults With ASD","enrollment":8},{"nctId":"NCT06035003","phase":"NA","title":"Mechanism of Mindfulness-Based Online Intervention in Enhancing Cognitive Flexibility","status":"UNKNOWN","sponsor":"Peking University","startDate":"2023-09-18","conditions":"Emotional Distress","enrollment":595},{"nctId":"NCT05889234","phase":"","title":"Multimodal Magnetic Resonance Imaging-based Study of Electroconvulsive Efficacy Prediction in Adolescents With Depression: a Multicenter Prospective Cohort Study","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2023-11-06","conditions":"Major Depressive Disorder, Magnetic Resonance Imaging, Electroconvulsive Therapy","enrollment":180},{"nctId":"NCT06040944","phase":"","title":"Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients","status":"COMPLETED","sponsor":"Fayoum University","startDate":"2022-09-01","conditions":"Schizophrenia Spectrum and Other Psychotic Disorders, Periodontal Diseases","enrollment":64},{"nctId":"NCT05891015","phase":"NA","title":"The Mechanism of Mindfulness Intervention to Alleviate Emotional Distress in Patients With Emotional Disorders","status":"UNKNOWN","sponsor":"Peking University","startDate":"2023-06-20","conditions":"Emotional Distress, Emotional Disorder","enrollment":200},{"nctId":"NCT05833399","phase":"","title":"Correlation of Genetic Variations With Clinical Response in Substance Use Disorder","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2022-11-28","conditions":"Substance Use Disorders, Substance Dependence","enrollment":200},{"nctId":"NCT04518319","phase":"PHASE2","title":"Clinical Intervention on Cognitive Impairment of Schizophrenia With Metabolic Syndrome","status":"SUSPENDED","sponsor":"Shanghai Mental Health Center","startDate":"2020-10-01","conditions":"Schizophrenia","enrollment":120},{"nctId":"NCT05803642","phase":"PHASE3","title":"A Study of Olanzapine in Patients With Acute Agitation","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2023-03-28","conditions":"Acute Agitation","enrollment":318},{"nctId":"NCT04750395","phase":"PHASE2","title":"Comparing Haloperidol and Olanzapine in Treating Terminal Delirium","status":"UNKNOWN","sponsor":"HCA Hospice Care","startDate":"2021-09-01","conditions":"Delirium, Terminal Illness","enrollment":80},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT05547100","phase":"PHASE1","title":"Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan","status":"COMPLETED","sponsor":"Alkermes, Inc.","startDate":"2022-09-14","conditions":"Focus of Study is on Healthy Lactating Women","enrollment":12},{"nctId":"NCT00568672","phase":"PHASE3","title":"Optimal Duration of Olanzapine Add-on Therapy in Major Depression","status":"WITHDRAWN","sponsor":"Charite University, Berlin, Germany","startDate":"2007-10","conditions":"Relapse Rate of a Major Depressive Episode, Safety of Olanzapine in Subjects With Major Depression","enrollment":""},{"nctId":"NCT05179772","phase":"PHASE2","title":"Olanzapine in OUD Patients","status":"WITHDRAWN","sponsor":"University of Pennsylvania","startDate":"2022-07-28","conditions":"Opioid Use Disorder","enrollment":""},{"nctId":"NCT05646264","phase":"PHASE4","title":"A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in Schizophrenia","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2023-01-01","conditions":"Schizophrenia, Negative Symptoms in Schizophrenia","enrollment":220},{"nctId":"NCT04341467","phase":"NA","title":"Amisulpride Treatment for BPSD in AD Patients","status":"UNKNOWN","sponsor":"Tianjin Anding Hospital","startDate":"2019-12-01","conditions":"BPSD, Amisulpride, Olanzapine","enrollment":76},{"nctId":"NCT05606224","phase":"NA","title":"The Effects and Mechanisms of Mindfulness Intervention for Emotional Distress","status":"UNKNOWN","sponsor":"Peking University","startDate":"2022-02-20","conditions":"Emotional Disorder","enrollment":200},{"nctId":"NCT05600790","phase":"NA","title":"Mechanism of Mindfulness Based Online Intervention in Reducing Emotional Distress","status":"UNKNOWN","sponsor":"Peking University","startDate":"2022-10-29","conditions":"Emotional Distress","enrollment":300},{"nctId":"NCT00845026","phase":"PHASE2","title":"A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2009-03","conditions":"Schizophrenia","enrollment":261},{"nctId":"NCT04002258","phase":"","title":"Prolactin Change in Chinese Patients With Schizophrenia After Antipsychotics Treatment","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2019-06-06","conditions":"Schizophrenia, Antipyretics Toxicity, Prolactin Excess","enrollment":10363},{"nctId":"NCT01052103","phase":"PHASE2","title":"A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2010-01","conditions":"Schizophrenia","enrollment":167},{"nctId":"NCT00273624","phase":"PHASE3","title":"Olanzapine Augmentation Therapy in Treatment-resistant Depression: a Double-blind Placebo-controlled Trial","status":"WITHDRAWN","sponsor":"University Hospital Freiburg","startDate":"2005-06","conditions":"Therapy-resistant Depression","enrollment":""},{"nctId":"NCT00448630","phase":"","title":"An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2007-10-23","conditions":"Schizophrenia, Metabolic Syndrome X","enrollment":328},{"nctId":"NCT00176436","phase":"PHASE4","title":"Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2004-02","conditions":"Schizophrenia","enrollment":40},{"nctId":"NCT00159783","phase":"PHASE3","title":"40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-07","conditions":"Bipolar Disorder","enrollment":218},{"nctId":"NCT03631004","phase":"PHASE2, PHASE3","title":"Pre-operative Olanzapine as Prophylactic Antiemetic in Oncologic Patients","status":"COMPLETED","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2018-10-01","conditions":"Postoperative Nausea, Postoperative Nausea and Vomiting","enrollment":100},{"nctId":"NCT05123976","phase":"PHASE1","title":"Fasted Bioequivalence Study of 2 Olanzapine Film-coated Tablets, 5 mg, in Healthy, Adult Male and Female Subjects.","status":"COMPLETED","sponsor":"Joint Stock Company \"Farmak\"","startDate":"2020-10-21","conditions":"Pharmacokinetics","enrollment":32},{"nctId":"NCT02213887","phase":"PHASE4","title":"Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications","status":"WITHDRAWN","sponsor":"University of British Columbia","startDate":"2014-09","conditions":"Psychotic Disorders, Gastroesophageal Reflux","enrollment":""},{"nctId":"NCT03019887","phase":"NA","title":"Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction","status":"COMPLETED","sponsor":"Juntendo University","startDate":"2011-04","conditions":"Schizophrenia Relapse","enrollment":139},{"nctId":"NCT00149292","phase":"PHASE2","title":"Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2005-08-23","conditions":"Schizophrenia","enrollment":195},{"nctId":"NCT03137121","phase":"PHASE2, PHASE3","title":"Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2017-07-12","conditions":"Advanced Cancer","enrollment":30},{"nctId":"NCT00149734","phase":"PHASE3","title":"Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2005-01","conditions":"Schizophrenia","enrollment":8},{"nctId":"NCT03451734","phase":"","title":"Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients","status":"COMPLETED","sponsor":"Central South University","startDate":"2018-01-23","conditions":"Schizophrenia, Metabolic Syndrome","enrollment":2000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"olanzapine therapy","genericName":"olanzapine therapy","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Acute agitation associated with schizophrenia or bipolar disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}